(P015) Delayed Cerebrovasculopathy Due to Cranial Radiation Therapy for Pediatric Tumors

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Radiation-induced cerebrovascular injury in the form of accelerated arteriosclerosis of blood vessels is a well-known phenomenon. Delayed cerebrovasculopathy in pediatric cancer patients as a result of cranial irradiation has been reported to present as Moyamoya disease or intracerebral hemorrhage.

Chenyang Wang, PhD, Kenneth B. Roberts, MD, Ranjit S. Bindra, MD, PhD, Veronica L. Chiang, MD, James B. Yu, MD; Department of Therapeutic Radiology and Department of Neurosurgery, Yale School of Medicine

Background: Radiation-induced cerebrovascular injury in the form of accelerated arteriosclerosis of blood vessels is a well-known phenomenon. Delayed cerebrovasculopathy in pediatric cancer patients as a result of cranial irradiation has been reported to present as Moyamoya disease or intracerebral hemorrhage. In this study, we propose to analyze reported cases of delayed radiation-induced cerebrovasculopathy that presents as Moyamoya disease and/or intracerebral hemorrhage and investigate the relationship between radiation dose and the interval between radiation and the presentation of cerebrovasculopathy.

Methods: Patients under 21 years of age at the time of radiation were included in analysis. Manuscript review yielded 77 cases of delayed radiation-induced cerebrovasculopathy, consisting of 45 cases of Moyamoya disease, 30 cases of intracerebral hemorrhage, and 2 cases of both. The total prescribed radiation dose and the interval between radiation and the onset of cerebrovasculopathy were determined for each case.

Results: The median age at radiation was 4.8 years, with a range of 0.5 to 20 years. Approximately 75% of these patients received radiation at less than 9 years of age. The median interval period from radiation to presentation for intracerebral hemorrhage cases was 7.5 years (range: 0.8–27 yr), whereas the median interval period for Moyamoya disease cases was 3.3 years (range: 0.3–20 yr) (P < .001). There was no significant association between radiation dose and interval from radiation to intracerebral hemorrhage presentation (P = .31), while for Moyamoya patients, the association was significant (P < .001).

Conclusions: Pediatric patients who presented with Moyamoya disease generally presented earlier than those who presented with intracerebral hemorrhage. This supports the possibility that Moyamoya may be an earlier manifestation of cerebrovasculopathy that precedes intracerebral hemorrhage. Furthermore, in patients who presented with Moyamoya, there was a statistically significant correlation between increasing doses of radiation and shorter time from radiation to disease presentation.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content